India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
A new national survey shows that while most real estate agents now use AI for everyday tasks like writing listing descriptions and social posts, many remain uneasy trusting the technology with higher‑stakes responsibilities. Agents report major time savings and better communication thanks to AI, but lingering concerns about accuracy, compliance and data interpretation reveal a growing skills gap. The industry’s next big need: stronger AI tools, clearer standards and hands‑on training — a gap education providers like Cameron Academy are poised to fill.
Florida homeowners and real estate professionals are being crushed by skyrocketing insurance premiums, shrinking coverage, and a claims system stacked against consumers. While residents face the highest insurance costs in the nation, meaningful reform bills are being ignored in Tallahassee, leaving families, businesses, and the entire real estate market exposed.
Artificial intelligence is exposing the real estate industry's biggest weakness: fragmented, inconsistent data scattered across disconnected systems. Unlike finance and e‑commerce, real estate never built a unified digital foundation—and now AI can’t function without one. As companies scramble to standardize information, organizations like OSCRE are pushing shared data models that could transform everything from leasing to property management. The result may be the industry’s most collaborative era yet, where clean, interoperable data becomes the key to unlocking AI’s full power.
Off‑market networks, rising small‑investor buying, regulatory shifts, and intensifying portal competition are reshaping how homes are found and sold. With inventory tight and traditional listings declining, agents who understand investor behavior, private deal flow, and evolving rules are gaining a major edge in today’s fast‑changing housing landscape.
Despite state leaders celebrating stabilization, Florida homeowners continue to face some of the highest insurance premiums in the country. Local experts say rates have stopped skyrocketing but have settled at levels that feel permanently elevated—especially for older or coastal homes. With insurers still avoiding high‑risk areas and demanding costly home upgrades, many Floridians are questioning whether this expensive reality is here to stay.
California is pushing a landmark proposal that would force insurers to offer coverage to homeowners who meet state‑approved wildfire‑mitigation standards. The new SB 1076, known as the Insurance Coverage for Fire‑Safe Homes Act, aims to stabilize the state’s distressed insurance market by guaranteeing coverage for fire‑hardened homes starting in 2028—backed by strict penalties for insurers who refuse. As supporters rally and critics warn of market strain, the bill could reshape real estate, insurance, and lending practices across wildfire‑prone regions.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
